{"id":63679,"name":"FULCRUM THERAPEUTICS","slug":"fulcrum-therapeutics","state":"MA","country":"United States of America","description":"Rare disease biopharma company","totalSpending":160000,"filings":5,"yearlySpending":[{"year":2025,"income":160000}],"issues":["HCR"],"firms":["THE MCMANUS GROUP"],"lobbyists":["LAWREN GEER","JOHN MCMANUS"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Sickle Cell disease education Orphan Drug Tax Credit Priority review vouchers","Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025","Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025","Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025","Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025"],"years":[2025]}